Article, News
Strong quarter for Prescient bolsters future of further trials
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter with a healthy $21.8 million cash balance that will serve…
Article, News
TechKnow Invest Roadshow
Hear Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke present at the TechKnow Invest Roadshow – Gold Coast.
Article, News
ASX Quarterly Wrap: Dimerix sees strong kidney drug trial recruitment, Prescient advances cancer therapy
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with update lodgements. To save you the trouble of trudging through…
Article, News
Health Kick Podcast: Prescient Therapeutics an emerging global leader in the next generation of personalised cancer therapies.
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. …
Article, News
Global Victoria HealthTech Talks – Regenerative Medicine
Victoria has a mature, internationally recognised and thriving ecosystem that supports research and translation of new Regenerative Medicine therapeutics for global markets. The field of…
Article, News
Prescient Therapeutics seeks to provide new tools for clinicians in combating cancer
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…
Article, News
Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR Platform
We can profile the patient, find out what they need, we pull the appropriate targeting ligand from the freezer, couple it to the cell we…
Article, News
Prescient bolsters board, abstracts showcased at prestigious conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive Dr Ellen Feigal as a Non-Executive Director of PTX. Dr…
Article, News
Prescient Therapeutics to present OmniCAR and CellPryme abstracts at international gene therapy conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell & Gene Therapy…
Article, News
Prescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene Therapy
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…